| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 1/50 | Human,Mouse,Rat |
| FCM | 1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Proto-oncogene tyrosine-protein kinase Src, Proto-oncogene c-Src, pp60c-src, p60-Src, SRC, SRC1 |
| Entrez GeneID | 6714 |
| WB Predicted band size | 59.8kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SRC antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 24-52 amino acids from the N-terminal region of human SRC. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SRC (N-term)抗体的参考文献示例(注：内容为示例性概括，非真实文献)：
---
1. **文献名称**：*Role of c-Src N-terminal domain in cancer cell migration and invasion*
**作者**：Lee et al.
**摘要**：本研究利用SRC (N-term)特异性抗体，通过免疫印迹和免疫荧光技术，分析了c-Src蛋白在多种癌细胞系中的表达及亚细胞定位。结果显示，N端结构域在调节Src激酶活性和介导细胞骨架重塑中起关键作用，与肿瘤转移密切相关。
2. **文献名称**：*Development of a high-specificity N-terminal SRC antibody for diagnostic applications*
**作者**：Zhang et al.
**摘要**：作者开发了一种针对SRC蛋白N端表位的单克隆抗体，并通过ELISA和免疫组化验证其特异性。该抗体成功用于区分SRC家族激酶的不同亚型，并在结直肠癌组织样本中检测到SRC的异常激活，为临床诊断提供了新工具。
3. **文献名称**：*SRC N-terminal phosphorylation regulates neuronal signaling pathways*
**作者**：Martinez-Reyes et al.
**摘要**：通过SRC (N-term)抗体结合质谱分析，研究发现神经元中SRC的N端磷酸化位点(Tyr15)参与调控突触可塑性和神经退行性疾病相关通路，揭示了该区域在神经功能中的分子机制。
4. **文献名称**：*Targeting SRC N-terminal domain for therapeutic intervention in breast cancer*
**作者**：Chen et al.
**摘要**：本研究利用SRC (N-term)抗体筛选小分子抑制剂，发现一种化合物可特异性结合N端结构域并抑制Src活性，显著降低乳腺癌细胞的增殖和侵袭能力，为靶向治疗提供潜在策略。
---
**说明**：以上文献为示例，实际引用需检索PubMed等数据库获取真实研究(可搜索关键词如“SRC N-terminal antibody”、“c-Src epitope mapping”)。经典文献可能涉及Src家族激酶的结构与功能(如：Thomas et al., *Cell* 1995)。
The SRC (N-term) antibody is a widely used tool in molecular biology and cancer research, specifically targeting the N-terminal region of the SRC proto-oncogene product. SRC, a non-receptor tyrosine kinase, plays pivotal roles in regulating cellular processes such as proliferation, differentiation, adhesion, and migration. Dysregulation of SRC kinase activity is strongly associated with tumor progression and metastasis in various cancers, including colorectal, breast, and pancreatic cancers.
The N-terminal region of SRC contains critical regulatory domains, including the SH3 (Src Homology 3) and SH2 domains, which mediate protein-protein interactions and modulate kinase activity. The SRC (N-term) antibody typically recognizes epitopes within these domains or adjacent sequences, enabling researchers to detect full-length SRC or its splice variants in techniques like Western blotting, immunoprecipitation, and immunofluorescence. This antibody helps distinguish SRC from related kinases (e.g., Yes, Fyn) and assess its activation state when combined with phospho-specific antibodies (e.g., pTyr416).
Developed using immunogens derived from the human SRC N-terminal sequence, these antibodies are validated for specificity across species (human, mouse, rat) and are essential in studying SRC's role in signaling pathways (e.g., EGFR, integrin) and therapeutic responses. Their applications extend to cancer biomarker studies, drug development targeting SRC-family kinases, and mechanistic investigations of cellular transformation.
×
